An update on molecular biology and drug resistance mechanisms of multiple myeloma

Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Critical reviews in oncology/hematology 2015-12, Vol.96 (3), p.413-424
Hauptverfasser:	Mutlu, Pelin, Kiraz, Yağmur, Gündüz, Ufuk, Baran, Yusuf
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Alkylating - pharmacology Drug Resistance Hematology, Oncology and Palliative Medicine Humans Male Molecular aspects Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Multiple Myeloma - pathology Targeted drug delivery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Multiple myeloma (MM), a neoplasm of plasma cells, is the second most common hematological malignancy. • Development of MM involves a series of complex molecular events, including chromosomal abnormalities, oncogene activation and growth factor dysregulation. • MM is a difficult disease to treat because of its marked resistance to chemotherapy. • This review deals with the molecular aspects of MM, drug resistance mechanisms during treatment and also possible new applications for overcoming drug resistance.
ISSN:	1040-8428 1879-0461
DOI:	10.1016/j.critrevonc.2015.07.003